# Phase 1/2 lung cancer trials recruiting: 60 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 60 trials in phase 1/2 for lung cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 lung cancer trials: 60 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/lung-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 60
- Recruiting or not yet: 60
- Read on: November 19, 2026

## Trials

The 25 newest of 60, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07902921 | STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic... | National Cancer Institute (NCI) | Phase 1/2 | Not yet recruiting | NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer, Thymic Epithelial Tumors, TETs, Thymic Carcinomas... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902921) |
| October 27, 2026 | NCT07897734 | TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and... | Tango Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer... | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897734) |
| October 8, 2026 | NCT07864584 | Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced... | Nob Hill Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864584) |
| June 5, 2026 | NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | Blueprint Medicines Corporation | Phase 1/2 | Recruiting | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629960) |
| May 22, 2026 | NCT07602855 | A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) | GlaxoSmithKline | Phase 1/2 | Recruiting | Neoplasms, Lung | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602855) |
| March 20, 2026 | NCT07486648 | Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib | Shanxi Province Cancer Hospital | Phase 1/2 | Not yet recruiting | Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Advanced Non-small-cell Lung Cancer | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486648) |
| February 25, 2026 | NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | Sichuan Enray Pharmaceutical Sciences Company | Phase 1/2 | Recruiting | Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer, Colorectal Cancer, Cervical Cancer, Vulva Cancer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07433283) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| January 21, 2026 | NCT07355231 | Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI | Xemed LLC | Phase 1/2 | Not yet recruiting | Carcinoma, Non-Small-Cell Lung | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07355231) |
| January 21, 2026 | NCT07354711 | A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors | 3H Pharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Lung Cancer, Stomach Cancer | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07354711) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| December 18, 2025 | NCT07292168 | A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast... | Kidney Cancer Research Bureau | Phase 1/2 | Recruiting | Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic, Non-small Cell Lung Cancer Metastatic, Breast Cancer... | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292168) |
| December 16, 2025 | NCT07286149 | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Lung Neoplasm Malignant | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286149) |
| December 16, 2025 | NCT07285148 | A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | Beijing Pearl Biotechnology Limited Liability Company | Phase 1/2 | Not yet recruiting | Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration | 253 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285148) |
| December 2, 2025 | NCT07260058 | Immune Cell Therapy for Advanced Solid Tumors | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | Phase 1/2 | Not yet recruiting | Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260058) |
| October 31, 2025 | NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants... | Bristol-Myers Squibb | Phase 1/2 | Recruiting | Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal... | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223047) |
| August 29, 2025 | NCT07148128 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced... | Auricula Biosciences Inc. | Phase 1/2 | Recruiting | Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in... | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07148128) |
| June 26, 2025 | NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors... | Avenzo Therapeutics, Inc. | Phase 1/2 | Recruiting | Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer... | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07038343) |
| June 13, 2025 | NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Verastem, Inc. | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS | 616 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020221) |
| June 10, 2025 | NCT07012031 | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a... | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07012031) |
| April 13, 2025 | NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours | Filamon LTD | Phase 1/2 | Recruiting | Prostate Cancers, Breast Cancer, Lung Cancers, Ovarian Cancer, Glioblastoma Multiforme (GBM), Pancreas Cancer, Skin... | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926075) |
| April 10, 2025 | NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Tango Therapeutics, Inc. | Phase 1/2 | Recruiting | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer... | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06922591) |
| March 26, 2025 | NCT06896890 | Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer | Inhatarget Therapeutics | Phase 1/2 | Recruiting | NSCLC (advanced Non-small Cell Lung Cancer), Stage IV Lung Cancer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06896890) |
| February 5, 2025 | NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Tango Therapeutics, Inc. | Phase 1/2 | Recruiting | Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell... | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810544) |
| October 1, 2024 | NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With... | Bristol-Myers Squibb | Phase 1/2 | Recruiting | Lung Cancer, Breast Cancer | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06618287) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 3 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 3 |
| Tango Therapeutics, Inc. | 3 |
| Essen Biotech | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| Vanderbilt-Ingram Cancer Center | 2 |
| Obsidian Therapeutics, Inc. | 1 |
| Kidney Cancer Research Bureau | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Filamon LTD | 1 |
| St. Joseph's Healthcare Hamilton | 1 |
| VA Office of Research and Development | 1 |
| PMV Pharmaceuticals, Inc | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| Hackensack Meridian Health | 1 |
| Nob Hill Therapeutics, Inc. | 1 |
| Auricula Biosciences Inc. | 1 |
| Inhibrx Biosciences, Inc | 1 |
| Xemed LLC | 1 |
| Hadassah Medical Organization | 1 |
| Frontier Medicines Corporation | 1 |
| Cancer Research UK | 1 |
| Phanes Therapeutics | 1 |
| Turning Point Therapeutics, Inc. | 1 |
| Beijing Pearl Biotechnology Limited Liability Company | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 38 |
| China | 15 |
| Spain | 12 |
| Australia | 10 |
| Canada | 9 |
| France | 9 |
| Italy | 7 |
| South Korea | 6 |
| United Kingdom | 6 |
| Germany | 5 |
| Netherlands | 4 |
| Taiwan | 4 |
| Japan | 3 |
| Singapore | 3 |
| Hong Kong | 3 |
| Denmark | 3 |
| Chile | 2 |
| Greece | 2 |
| Israel | 2 |
| Belgium | 2 |
| Puerto Rico | 2 |
| Russia | 1 |
| Brazil | 1 |
| Austria | 1 |
| Czechia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Spine surgery practices in the United States](https://specstream.ai/data/businesses/spine-surgery-practices/united-states)
- [Nursing services in the United States](https://specstream.ai/data/businesses/nursing-services/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Clothing companies in the United States](https://specstream.ai/data/businesses/clothing-companies/united-states)
- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
- [Restaurant wholesale companies in the United States](https://specstream.ai/data/businesses/restaurant-wholesale-companies/united-states)
